Page last updated: 2024-12-08
gla 27
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
GLA 27: nonreducing sugar part of lipid A analog with interferon-inducing, tumor necrosis factor-inducing, but not pyrogenic acitivity; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 163574 |
| MeSH ID | M0140658 |
Synonyms (9)
| Synonym |
|---|
| gla 27 |
| 89756-57-0 |
| [1-[[(2r,3r,4r,5r)-5,6-dihydroxy-1-oxo-4-phosphonooxy-3-tetradecanoyloxyhexan-2-yl]amino]-1-oxotetradecan-3-yl] tetradecanoate |
| 3-o-tetradecanoyl-2n-3-tetradecanoyloxytetradecanoyl-4-o-phosphonoglucosamine |
| 2-deoxy-4-o-phosphono-3-o-tetradecanoyl-2-(3-tetradecanoyloxytetradecanamido)-d-glucose |
| gla-27 |
| d-glucose, 2-deoxy-2-((1-oxo-3-((1-oxotetradecyl)oxy)tetradecyl)amino)-, 4-(dihydrogen phosphate) 3-tetradecanoate |
| DTXSID401008960 |
| 2-deoxy-2-{[1-hydroxy-3-(tetradecanoyloxy)tetradecylidene]amino}-4-o-phosphono-3-o-tetradecanoylhexose |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (70.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.65
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.65) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||